U.S. markets closed
  • S&P Futures

    4,367.25
    +19.00 (+0.44%)
     
  • Dow Futures

    34,031.00
    +192.00 (+0.57%)
     
  • Nasdaq Futures

    15,062.75
    +53.25 (+0.35%)
     
  • Russell 2000 Futures

    2,189.00
    +12.20 (+0.56%)
     
  • Crude Oil

    70.98
    +0.69 (+0.98%)
     
  • Gold

    1,762.90
    -0.90 (-0.05%)
     
  • Silver

    22.25
    +0.05 (+0.23%)
     
  • EUR/USD

    1.1736
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    1.3090
    -0.0610 (-4.45%)
     
  • Vix

    25.71
    +4.90 (+23.55%)
     
  • GBP/USD

    1.3670
    +0.0011 (+0.08%)
     
  • USD/JPY

    109.5920
    +0.1720 (+0.16%)
     
  • BTC-USD

    42,652.87
    -2,977.80 (-6.53%)
     
  • CMC Crypto 200

    1,066.57
    -67.82 (-5.98%)
     
  • FTSE 100

    6,903.91
    -59.73 (-0.86%)
     
  • Nikkei 225

    29,894.67
    -605.38 (-1.98%)
     

ChemoCentryx to Participate in the Canaccord Genuity 41st Annual Growth Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 5:00 p.m. ET.

A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. A replay of the webcast will be available on the Company's website for two weeks following the live presentation.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and is in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:
Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Lee Roth, Burns McClellan
212.213.0006
lroth@burnsmc.com